$148.00
Tesamorelin(10mg) is a synthetic growth hormone-releasing hormone (GHRH) analog developed to stimulate endogenous growth hormone (GH) secretion. It is FDA-approved for reducing excess abdominal (visceral) fat in patients with HIV-associated lipodystrophy. By increasing GH and IGF-1 levels, Tesamorelin promotes lipolysis while preserving lean body mass. It is also being investigated for broader metabolic and fat-reduction benefits, including potential applications in non-HIV-related obesity and non-alcoholic fatty liver disease (NAFLD).
22 in stock
Tesamorelin acetate (an analogue of human growth hormone).
It’s a sugar alcohol used as a filler or bulking agent.
The main research focus tesamorelin peptide is on reducing the abdominal fat in HIV patients, as it reduces about 15% on the visceral adipose tissues after 2 and a half years.
Various studies indicate that tesamorelin (10 mg) can reduce liver fat and also prevent the progression of liver fibrosis. As it explores its use in patients along with NAFLD.
Apart from reducing fat quality, the tesamorelin peptide can improve the metabolic quality of subcutaneous and visceral adipose tissue in people with HIV.
Tesamorelin binds and activates with GHRH on receptors and somatotrophs in the anterior and pituitary glands
Once these receptors are triggered, they trigger the synthesis of the pulsatile and endogenous growth hormone.
Tesamorelin is FDA-approved to reduce the stubborn fat around the abdomen and organs in HIV patients. It also increases the antiretroviral therapy
It’s associated with reductions in triglycerides and cholesterol control.
Various studies indicate it can reduce the liver fat in patients with HIV associated with abdominal obesity.
Study focus: Tesamorelin vs placebo over 26 weeks
Findings: 15–20% VAT reduction with no significant subcutaneous fat loss
Study focus: Blood lipid markers
Findings: Lowered triglycerides and improved cholesterol ratios
Study focus: Tesamorelin’s effect on hepatic fat in HIV patients
Findings: Up to 37% relative reduction in liver fat over 12 months
Study focus: 52-week treatment extension
Findings: Continued therapy maintained fat loss and improved body image/lipid profiles
Study focus: Glucose tolerance over time
Findings: No clinically significant changes in glucose or insulin markers
Note : Please review and adhere to our Terms and Conditions before ordering
Sequence:His-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Glu-Gln-Gly-Gln-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Molecular Formula:C^221H^366N^72O^67**S
Molecular Weight:5135.85 g/mol
TB-500 peptide is modelled after Thymosin Beta-4 (Tβ4), a naturally occurring peptide involved in cellular healing and regeneration. TB-500 is designed to promote recovery, reduce inflammation, and support tissue regeneration across muscle, tendon, ligament, and skin systems. It is especially popular in sports medicine and regenerative therapy for its ability to enhance cell migration and angiogenesis.
| Quantity | 10mg |
|---|
NAD⁺ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme present in all living cells, critical to energy metabolism, DNA repair, mitochondrial function, and cellular signalling. It exists in oxidized (NAD⁺) and reduced (NADH) forms and plays a central role in ageing, neurodegeneration, immunity, and metabolic health. As NAD⁺ levels decline with age, supplementation strategies (e.g., NMN, NR) are being explored to enhance healthspan and lifespan.
| Quantity | 1000mg |
|---|
GLP-1 R activates GLP-1, GIP, and glucagon receptors and is used in laboratory research to study metabolic pathways, receptor activity, and peptide interactions. Compounds like this are commonly studied in preclinical and research settings to explore potential therapeutic mechanisms.
| Quantity | 16mg, 24mg |
|---|
ARA 290 is a non-erythropoietic peptide that offers neuroprotection, pain relief, anti-inflammation, and tissue repair, especially for neuropathy.
| Quantity | 16mg |
|---|
